Drugs / lipoic acid
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 2 missed | ||||||
| Phase 1/2 | NCT02133664 | Jun 2014 → May 2016 | multiple sclerosis | Oregon Health and Science University | Completed | Missed primary |
| Phase 1/2 | NCT01058941 | Sep 2010 → Dec 2014 | Alzheimer disease | Oregon Health and Science University | Completed | Missed primary |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT03161028 | Aug 2018 → Dec 2023 | multiple sclerosis | VA Office of Research and Development | Completed | Missed primary |
| Phase 2 | NCT01495260 | Sep 2011 → Nov 2013 | adrenomyeloneuropathy | Pujol, Aurora, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT00398892 | Dec 2009 → Jan 2011 | type 2 diabetes mellitus | University of Edinburgh | Withdrawn | No outcome recorded |
| Phase 2 | NCT00065624 | Nov 2003 → Jul 2007 | hyperlipidemia | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT01188811 | Oct 2010 → Aug 2015 | chronic progressive multiple sclerosis | VA Office of Research and Development | Completed | Met primary |
| Phase not applicable2 trials · 1 met primary | ||||||
| — | NCT06122012 | May 2023 → Apr 2024 | diabetic polyneuropathy | Haisco Pharmaceutical Group Co., Ltd. | Unknown | Met primary |
| — | NCT04518540 | Sep 2020 → Sep 2022 | amyotrophic lateral sclerosis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT01294176 Comparator | Jan 2011 → Nov 2016 | optic neuritis | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1 | NCT00676156 Comparator | Dec 2005 → Feb 2008 | multiple sclerosis | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1/2 | NCT05507697 Comparator | May 2022 → May 2024 | diabetic polyneuropathy | Wuhan Central Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00962429 Comparator | Feb 2009 → Jan 2013 | chronic inflammatory demyelinating polyradiculoneuropathy | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2/3 | NCT01224353 Comparator | Nov 2010 → May 2011 | — | NovaMed Pharmaceuticals Inc. | Unknown | No outcome recorded |
| — | NCT05000463 Background | Feb → Aug 2022 | chronic pain syndrome | Assiut University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lipoic acid | “HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；” NCT06122012 ↗14“The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.” NCT05000463 ↗ |
| Route | Oral | “lipoic acid supplements taken orally” NCT00398892 ↗ |